When does new onset diabetes resulting from antihypertensive therapy increase cardiovascular risk

被引：14

作者：

Bakris, GL

Sowers, JR

机构：

[1] Rush Univ, Med Ctr, Hypertens Clin Res Ctr, Chicago, IL 60612 USA

[2] Univ Missouri, Hlth Sci Ctr, Columbia, MO USA

来源：

HYPERTENSION | 2004年 / 43卷 / 05期

关键词：

D O I：

10.1161/01.HYP.0000125727.92964.e2

中图分类号：

R6 [外科学];

学科分类号：

1002 ; 100210 ;

摘要：

引用

页码：941 / 942

页数：2

共 14 条

[1] Cardiovascular disease in older adults with glucose disorders: comparison of American Diabetes Association criteria for diabetes mellitus with WHO criteria
Barzilay, JI
Spiekerman, CF
Wahl, PW
Kuller, LH
Cushman, M
Furberg, CD
Dobs, A
Polak, JF
Savage, PJ
[J]. LANCET, 1999, 354 (9179) : 622 - 625
[2] Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) Trial
Black, HR
Elliott, WJ
Grandits, G
Grambsch, P
Lucente, T
White, WB
Neaton, JD
Grimm, RH
Hansson, L
Lacourcière, Y
Muller, J
Sleight, P
Weber, MA
Williams, G
Wittes, J
Zanchetti, A
Anders, RJ
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 289 (16): : 2073 - 2082
[3] Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT)
Brown, MJ
Palmer, CR
Castaigne, A
de Leeuw, PW
Mancia, G
Rosenthal, T
Ruilope, LM
[J]. LANCET, 2000, 356 (9227) : 366 - 372
[4] Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):: a randomised trial against atenolol
Dahlöf, B
Devereux, RB
Kjeldsen, SE
Julius, S
Beevers, G
de Faire, U
Fyhrquist, F
Ibsen, H
Kristiansson, K
Lederballe-Pedersen, O
Lindholm, LH
Nieminen, MS
Omvik, P
Oparil, S
Wedel, H
[J]. LANCET, 2002, 359 (9311) : 995 - 1003
[5] Furberg CD, 2002, JAMA-J AM MED ASSOC, V288, P2981
[6] Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus
Gress, TW
Nieto, FJ
Shahar, E
Wofford, MR
Brancati, FL
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (13) : 905 - 912
[7] CARDIOVASCULAR RISK-FACTORS IN CONFIRMED PREDIABETIC INDIVIDUALS - DOES THE CLOCK FOR CORONARY HEART-DISEASE START TICKING BEFORE THE ONSET OF CLINICAL DIABETES
HAFFNER, SM
STERN, MP
HAZUDA, HP
MITCHELL, BD
PATTERSON, JK
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1990, 263 (21): : 2893 - 2898
[8] Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension:: the Captopril Prevention Project (CAPPP) randomised trial
Hansson, L
Lindholm, LH
Niskanen, L
Lanke, J
Hedner, T
Niklason, A
Luomanmäki, K
Dahlöf, B
de Faire, U
Mörlin, C
Karlberg, BE
Wester, PO
Björck, JE
[J]. LANCET, 1999, 353 (9153) : 611 - 616
[9] Insulin resistance and cardiovascular disease
McFarlane, SI
Banerji, M
Sowers, JR
[J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (02) : 713 - 718
[10] MYKKANEN L, 1994, J HYPERTENS, V12, P1425

← 1 2 →